熱門資訊> 正文
Sangamo Therapeutics 2024年第二季度GAAP每股收益$（0.18）错过$（0.16）估计，销售额356.000 K美元错过826万美元估计
2024-08-07 05:29
Sangamo Therapeutics (NASDAQ: SGMO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $356.000 thousand which missed the analyst consensus estimate of $8.260 million by 95.69 percent. This is a 94.79 percent decrease over sales of $6.835 million the same period last year.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
